Shah, M. A., Wainberg, Z. A., Catenacci, D. V. T., Hochster, H. S., Ford, J., Kunz, P., . . . Bottaro, D. P. (2013). Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. Public Library of Science (PLoS).
Chicago Style (17th ed.) CitationShah, Manish A., et al. Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), CMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Public Library of Science (PLoS), 2013.
MLA (9th ed.) CitationShah, Manish A., et al. Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), CMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Public Library of Science (PLoS), 2013.
Warning: These citations may not always be 100% accurate.